Skip to main content
Catherine Hankins

Catherine Hankins

Forum Advisory Group member since 2008

Catherine Hankins’ current scientific interests include COVID-19, novel biomedical HIV prevention, implementation science and participatory research conduct. She is keenly interested in scientific capacity development and advancing women in global health and science. She is the AIGHD co-principal investigator for two CAPRISA trials of long-acting technologies for the prevention of HIV acquisition in young women. These are CAPRISA 012 (combination monoclonal antibodies, South Africa, Zambia) and CAPRISA 018 (sustained-release tenofovir alafenamide subdermal implant, South Africa). She was Scientific Chair and Organising Committee Chair for six of the Amsterdam Institute for Global Health and Development’s (AIGHD’s) annual INTEREST conferences on HIV treatment, pathogenesis and prevention research in resource-limited settings (2015 Harare, 2016 Yaoundé, 2017 Lilongwe, 2018 Kigali, 2019 Accra, 2020 Windhoek, virtual). She is the Scientific Co-Chair of the Eastern Europe and Central Asia INTERACT Workshop (2019 Almaty, 2021 virtual).

In April 2020, she was appointed Co-Chair of Canada’s COVID-19 Immunity Task Force, which catalyses, supports, funds and harmonizes research on SARS-CoV-2 immunity for decision –makers. The task force is generating critical insights on levels, trends, nature and duration of immunity arising from SARS-CoV-2 infection and COVID-19 vaccination. Since 2017, she has chaired the Scientific Advisory Committee of the European and Developing Countries Clinical Trials Partnership 2. In 2016, she led the development of good participatory practice guidelines for trials of emerging pathogens for the World Health Organization’s R&D blueprint.

For a decade before coming to AIGHD, she was the Chief Scientific Adviser to UNAIDS in Geneva. She led the scientific knowledge translation team focused on ensuring ethical and participatory biomedical HIV prevention trial conduct, convening mathematical modelling teams, and supporting country implementation of proven biomedical HIV prevention modalities. She has participated in programme committees for numerous conferences. She was the Lead Rapporteur for Implementation Science at IAS 2017, the 9th IAS Conference on HIV Science, in Paris, and Track D Co-Chair (social and political research, law, policy and human rights) for AIDS 2018, the 22nd International AIDS Conference, in Amsterdam. She was a member of the Track E (implementation science) committee for AIDS 2022, the 23rd International AIDS Conference in Montreal.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.